Krystal Biotech, Inc. reported significant financial growth in its latest quarterly results, with product revenue reaching $116.4 million for the three months ended March 31, 2026, a 32% increase from $88.2 million in the same period last year. This growth is primarily attributed to the continued commercialization of VYJUVEK, the company's gene therapy product approved for treating dystrophic epidermolysis bullosa (DEB). The company also reported a net income of $55.9 million, a 57% increase compared to $35.7 million in the prior year, reflecting improved operational efficiency and increased sales.
Operating expenses for the quarter totaled $62.7 million, up 21% from $51.9 million in the previous year. The increase was driven by higher selling, general, and administrative expenses, which rose by 26% to $41 million, largely due to increased payroll costs and expenses related to global commercialization efforts. Research and development expenses also increased by 8% to $15.3 million, reflecting ongoing investments in the company's product pipeline.
In terms of operational metrics, Krystal Biotech's cash and cash equivalents stood at $501.3 million as of March 31, 2026, up from $496.3 million at the end of 2025. The company reported a total of $1.4 billion in assets, with total liabilities of $120.2 million, resulting in stockholders' equity of $1.3 billion. The company’s accounts receivable related to VYJUVEK sales remained stable at $127 million, indicating consistent demand for the product.
Looking ahead, Krystal Biotech is focused on expanding its market presence, particularly in Europe and Japan, where it launched VYJUVEK in 2025. The company is currently engaged in pricing negotiations in Germany and France, with plans to initiate launches in Italy and Spain later this year. Management believes that its current cash reserves will be sufficient to fund operations for at least the next 12 months, although they may seek additional capital to support ongoing clinical trials and commercialization efforts. The company remains optimistic about its growth trajectory, driven by the successful commercialization of VYJUVEK and advancements in its product pipeline.
About Krystal Biotech, Inc.
Krystal Biotech is a biotechnology company specializing in gene therapies for rare and serious diseases. Using its proprietary HSV-1 platform, it develops and commercializes treatments like VYJUVEK for dystrophic epidermolysis bullosa and pipeline candidates for ophthalmology, respiratory, oncology, and dermatology. The company focuses on non-invasive, repeatable gene delivery to address high unmet medical needs globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.